• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Study Suggests Patients Prefer Serono Fertility Treatment

Posted on: Tuesday, 26 September 2006, 06:00 CDT

Serono has reported the results of a phase IIIb, prospective, open-label study in which patients said that they preferred the Gonal-f RFF Pen to their previous fertility treatment with conventional vials and syringes.

"Patient satisfaction is a critical component to infertility treatment success," said Stephen Somkuti, the lead author and coordinating investigator from Abington Reproductive Medicine. "By providing products that patients prefer, fertility centers may minimize treatment dropout rates while increasing the chance of a positive outcome."

All participants who stated an injection preference found use of the Gonal-f RFF Pen to be less stressful than methods involving vials/ampules and syringes with 95% confidence and would recommend it to other women considering fertility treatment. In addition, 89% of patients found instructions for using the Pen very easy to understand compared with 29% who found the same for vials/ampules and syringes.

Gonal-f is a highly consistent recombinant form of human follicle stimulating hormone (r-hFSH) prescribed to supplement or replace naturally occurring FSH, which stimulates the development of follicles in the ovaries. A prefilled and ready-to-use multi-dose device, Gonal-f RFF Pen delivers a liquid formulation of Gonal-f RFF without needing to mix medications or load cartridges.

About 12% of women in the US aged 15 to 44 had difficulty getting pregnant or carrying a baby to term in 2002, according to the National Center for Health Statistics of the Centers for Disease Control and Prevention.

Source: Datamonitor

More News in this Category